Alex Sapir
Tracked across 1 events · 6 articles · First seen Jun 02, 2026 · Last active Jun 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Fulcrum Therapeutics, a publicly traded company, experienced a 50% stock plunge on June 1, 2026, after disclosing United States — Food and Drug Administration safety concerns related to the PRC2 inhibitor drug class, specifically regarding…
Impact: Alex Sapir, CEO of Fulcrum Therapeutics, made statements about pociredir's tolerability and competitive lead that are now under investigation for being potentially misleading prior to the FDA's safety concerns.
Jun 02, 2026 · 6 articles
NEWSDESK
Track Alex Sapir live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard